Literature DB >> 6728869

Clozapine--a serotonin antagonist?

H Fink, R Morgenstern, W Oelssner.   

Abstract

The effect of clozapine on the central serotonergic transmission system was studied by investigation of open-field motility of rats after microinjection of drugs into nucleus accumbens and median raphe nucleus. Previous work has shown that LSD in low doses potentiates apomorphine-induced hypermotility and that this LSD effect is induced by a serotonin agonist action in median raphe nucleus. Clozapine, injected into median raphe nucleus (0.05 micrograms), suppressed the LSD effect in the same manner as serotonin antagonists did. Since alpha-adrenergic drugs, injected into median raphe nucleus, caused locomotor stimulant effects, an alpha- adrenalytic action of clozapine was excluded. Clozapine, injected into nucleus accumbens (0.2 micrograms), increased apomorphine-induced hypermotility, whereas the dopamine antagonist haloperidol suppressed it. Our results suggest a serotonin antagonist action of clozapine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6728869     DOI: 10.1016/0091-3057(84)90297-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

1.  Multiple neurochemical action of clozapine: a quantitative autoradiographic study of DA2, opiate and benzodiazepine receptors in the rat brain after long-term treatment.

Authors:  L Giardino; L Calzà; P V Piazza; G Amato
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  The presynaptic component of the serotonergic system is required for clozapine's efficacy.

Authors:  Prem N Yadav; Atheir I Abbas; Martilias S Farrell; Vincent Setola; Noah Sciaky; Xi-Ping Huang; Wesley K Kroeze; LaTasha K Crawford; David A Piel; Michael J Keiser; John J Irwin; Brian K Shoichet; Evan S Deneris; Jay Gingrich; Sheryl G Beck; Bryan L Roth
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

3.  Atypical neuroleptics suppress dopaminergic behavioral supersensitivity.

Authors:  C Schremmer; R Morgenstern; H Fink; T Ott
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Acute dystonia due to clozapine.

Authors:  O Kastrup; M Gastpar; M Schwarz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

6.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 7.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 8.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

Review 9.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.

Authors:  J L Andersson; G G Nomikos; M Marcus; P Hertel; J M Mathé; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.